MedPath

Pilot Study Evaluating the Toray Satake Balloon Thermal Ablation System for Treatment of Paroxysmal Atrial Fibrillation

Not Applicable
Completed
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Device: Ablation
Registration Number
NCT01997736
Lead Sponsor
Toray Industries (America), Inc.
Brief Summary

The purpose of this study is to collect preliminary safety and effectiveness data evaluating the Toray Satake Balloon Thermal Ablation System (TSB)to treat subjects with symptomatic paroxysmal atrial fibrillation that is resistant to antiarrhythmic drug therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
41
Inclusion Criteria
  • Diagnosis of recurrent symptomatic paroxysmal atrial fibrillation
  • ≥2 Symptomatic atrial fibrillation episodes
  • At least 1 paroxysmal atrial fibrillation episode documented by an ECG or device recording system in the 6 months prior to enrollment AND
  • At least 1 additional (for a total of ≥2) paroxysmal atrial fibrillation episode documented by an ECG or device recording system, OR, at a minimum, a physician's note indicating recurrent symptomatic atrial fibrillation
  • No episode >7 days
  • Failed to respond to or is intolerant of ≥1 Class I, II, III or IV antiarrhythmic drug
  • Able and willing to provide informed consent and Health Insurance Privacy and Portability Act (HIPAA) authorization
  • Able and willing to meet all study requirements, including attending all post-ablation procedure assessments and visits
Exclusion Criteria
  • Left atrium ≥50 mm
  • Chronically used amiodarone in the 3 months prior to enrollment
  • Previous left atrial ablation or surgical treatment for atrial fibrillation
  • Left ventricular ejection fraction (LVEF) <35 %
  • New York Heart Association (NYHA) Class III or IV heart failure
  • History of myocardial infarction (MI) or unstable angina in the 6 months prior to enrollment
  • Multiple other exclusion criteria to establish overall good health and likely study compliance

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
AblationAblation-
Primary Outcome Measures
NameTimeMethod
Occurrence of major complications6 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

Mount Sinai Hospital

🇺🇸

New York, New York, United States

Texas Cardiac Arrhythmia Research Foundation

🇺🇸

Austin, Texas, United States

William Beaumont Hospital, Royal Oak

🇺🇸

Royal Oak, Michigan, United States

Medical University of South Carolina (MUSC)

🇺🇸

Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath